Advanced in Infantile Neutropenia

Dr. Barry J. Byrne

Pediatric Cardiology | Pediatrics
1600 Sw Archer Rd, 
Gainesville, FL 
Accepting New Patients
Advanced in Infantile Neutropenia
1600 Sw Archer Rd, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barry Byrne is a Pediatric Cardiologist and a Pediatrics provider in Gainesville, Florida. Dr. Byrne is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Pompe Disease, Barth Syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Bone Marrow Aspiration. Dr. Byrne is currently accepting new patients in some locations.

His clinical research consists of co-authoring 200 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Infantile Neutropenia.

Specialties
Pediatric Cardiology
Pediatrics
Licenses
Pediatric Cardiology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1600 Sw Archer Rd, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Genetic
Study Drug: SGT-001 Adeno-Associated Virus Microdystrophin Construct
Study Phase: Phase 1/Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Natural History Study in Children With a TECPR2 Mutation
A Natural History Study in Children With a TECPR2 Mutation
Enrollment Status: Completed
Publish Date: September 11, 2023
Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease
Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease
Enrollment Status: No_longer_available
Publish Date: August 23, 2023
Intervention Type: Drug
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug, Other, Genetic
Study Drugs: Rapamycin, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream, Adeno-Associated Virus Acid Alpha Glucosidase
Study Phase: Phase 1
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of Diet and Exercise Therapy in Pompe Disease
A Pilot Study of Diet and Exercise Therapy in Pompe Disease
Enrollment Status: Completed
Publish Date: May 14, 2021
Intervention Type: Other
Study Phase: Not Applicable
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: July 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy
Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: July 08, 2019
Intervention Type: Other
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: January 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Enrollment Status: Terminated
Publish Date: December 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: December 08, 2017
Intervention Type: Drug
View 19 Less Clinical Trials

200 Total Publications

A respiratory signature of disease progression in the Pompe rat.
A respiratory signature of disease progression in the Pompe rat.
Journal: Journal of neurophysiology
Published: December 05, 2025
Similar Doctors
Experienced in Infantile Neutropenia
Dr. James L. Wynn
Neonatology | Pediatrics
Experienced in Infantile Neutropenia
Dr. James L. Wynn
Neonatology | Pediatrics
1600 Sw Archer Rd, 
Gainesville, FL 
 (0.1 miles away)
352-273-8985
Languages Spoken:
English
See accepted insurances

James Wynn is a Neonatologist and a Pediatrics provider in Gainesville, Florida. Dr. Wynn is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Neonatal Sepsis, Premature Infant, Necrotizing Enterocolitis, and Intraventricular Hemorrhage of the Newborn.

Experienced in Infantile Neutropenia
Dr. Klaas Wierenga
Medical Genetics | Pediatrics
Experienced in Infantile Neutropenia
Dr. Klaas Wierenga
Medical Genetics | Pediatrics

Florida Clinical Practice Association Inc

1600 Sw Archer Rd, Suite 100371, 
Gainesville, FL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances

Klaas Wierenga is a Medical Genetics specialist and a Pediatrics provider in Gainesville, Florida. Dr. Wierenga is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Hypotonia, Nevoid Basal Cell Carcinoma Syndrome, Smith-Magenis Syndrome, and Ehlers-Danlos Syndrome (EDS).

Experienced in Infantile Neutropenia
Dr. Melissa E. Elder
Pediatric Rheumatology | Pediatrics
Experienced in Infantile Neutropenia
Dr. Melissa E. Elder
Pediatric Rheumatology | Pediatrics

Florida Clinical Practice Association Inc

1600 Sw Archer Rd, Suite 100371, 
Gainesville, FL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Melissa Elder is a Pediatric Rheumatologist and a Pediatrics provider in Gainesville, Florida. Dr. Elder is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Pignata Guarino Syndrome, Juvenile Idiopathic Arthritis (JIA), Pompe Disease, and Piebaldism. Dr. Elder is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byrne's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile